| abstract |
The present invention relates to an anti-c-Met antibody showing enhanced stability or antigen-binding fragments thereof, and the use thereof. Compared to 1E4 which is a parent antibody, the anti-c-Met antibody showing enhanced stability or antigen-binding reduced immunogenicity. Therefore, the anti-c-Met antibody or antigen-binding fragments thereof according to the present invention exhibits, in anti-c-Met antibody development, excellent properties such as reduced production cost, inhibition of reduced efficacy, reduced side effects and the like. |